+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Myeloproliferative Disorders (MPD) Treatment Market - Growth, Trends, and Forecast (2020-2025)

  • ID: 4997485
  • Report
  • March 2020
  • Region: Global
  • 115 pages
  • Mordor Intelligence
1 of 4

FEATURED COMPANIES

  • AbbVie
  • Bristol-Myers Squibb
  • Incyte Corporation
  • Mylan N.V.
  • Novartis AG
  • Pfizer
  • MORE
The global myeloproliferative disorders drugs market is anticipated to grow significantly during the forecast period due to the increasing prevalence of the various myeloproliferative disorders, presence of strong pipeline products, frequent product approvals and growing R&D investments on the development of novel drugs for MPD Treatment market.

According to National Organization for Rare Disorders (NORD), men are more likely affected than women with Polycythemia vera. The disorder is anticipated to affect around 2 people per 100,000 in the general population. It occurs most often in individuals aged more than 60 years old but can affect individuals of any age.

However, side effects associated with the chemotherapy medications might hamper the growth of the market studied.

Key Market Trends

Myelofibrosis segment Holds Significant Share in MPD Treatment Market

Myelofibrosis is a group of rare cancers of bone marrow in which the marrow is replaced by scar tissue and is not able to make healthy blood cells. It is classified as a type of chronic leukemia and belongs to a group of blood disorders called myeloproliferative diseases. It is also called as primary myelofibrosis, chronic idiopathic myelofibrosis or myelosclerosis with myeloid metaplasia.

According to National Organization for Rare Disorders (NORD), the true incidence of MF is not known but estimated to be approximately 1-1.5 per 100,000 people and is likely higher due to under-diagnosing and under-reporting.

Frequent product launches of the drugs for the treatment of Myelofibrosis is expected to drive the segment in the market studied. For instance, in September 2019, Sierra Oncology Inc. received U.S. Food and Drug Administration (FDA) Fast Track designation approval to its momelotinib, a JAK1, JAK2 and ACVR1 inhibitor for the treatment of patients with intermediate/high-risk myelofibrosis who have previously received a JAK inhibitor.

North America dominate the Global Myeloproliferative Disorders Treatment Market

North America dominates the global MPD treatment market owing to the increase in prevalence of Myelodysplastic Syndrome, early adoption of the novel treatments, high R&D investments on the development of the novel drugs, presence of sophisticated healthcare infrastructure.

For instance, in August 2019, Celgene Corporation (Acquired by Bristol-Myers Squibb) received U.S. Food and Drug Administration (FDA) approval to its INREBIC (fedratinib) for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis.

Asia Pacific is expected to experience a lucrative growth in the Global Myeloproliferative Disorders Treatment market due to the developing healthcare infrastructure, rapidly improving economic conditions, and promising regulatory environment for new Treatment.

Competitive Landscape

In the market studied, major players are focused on expanding their business in different areas by adopting various market strategies such as partnerships, collaborations, acquisitions and mergers etc. Key developments in the market include - in January 2019, Takeda Pharmaceutical Company Limited has completed the acquisition of Shire Plc one of the major player in the development of novel drugs for the treatment of Myeloproliferative Disorders.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format.
  • 3 months of analyst support.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbVie
  • Bristol-Myers Squibb
  • Incyte Corporation
  • Mylan N.V.
  • Novartis AG
  • Pfizer
  • MORE
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 High R & D investments on Development of Novel Treatments for MPD
4.2.2 Strong Presence of Pipeline Drugs
4.3 Market Restraints
4.3.1 Side Effects Associated with the Medications
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Type of MPD
5.1.1 Polycythaemia Vera
5.1.2 Essential Thrombocythemia
5.1.3 Myelofibrosis
5.1.4 Others
5.2 By Treatment
5.2.1 Chemotherapy
5.2.2 Immunotherapy
5.2.3 Stem Cell Transplantation
5.2.4 Others
5.3 By End-User
5.3.1 Hospitals
5.3.2 Specialty Clinics
5.3.3 Others
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 AbbVie
6.1.2 Bristol-Myers Squibb
6.1.3 Incyte Corporation
6.1.4 Mylan N.V.
6.1.5 Novartis AG
6.1.6 Pfizer
6.1.7 Teva Pharmaceuticals
6.1.8 Takeda Pharmaceutical Company Limited

7 MARKET OPPORTUNITIES AND FUTURE TRENDS
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • AbbVie
  • Bristol-Myers Squibb
  • Incyte Corporation
  • Mylan N.V.
  • Novartis AG
  • Pfizer
  • Teva Pharmaceuticals
  • Takeda Pharmaceutical Company Limited
Note: Product cover images may vary from those shown
Adroll
adroll